MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...
MSD has fleshed out the results of phase 3 trials of its cholesterol-lowering, oral PCSK9 inhibitor, enlicitide decanoate, showing its efficacy was comparable to that of injectable alternatives. The ...
Monday - Friday, 6:00 - 9:00 AM ET A Right Arrow icon United States Monday - Friday 6a ET Europe Monday - Friday 13:00 CET Asia Monday - Friday 18:00 SIN/HK Australia Monday - Friday 20:00 SYD "Squawk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results